APA

Pratap J., Akech J., Wixted J. J., Szabo G., Hussain S., McGee-Lawrence M. E., Li X., Bedard K., Dhillon R. J., van Wijnen A. J., Stein J. L., Stein G. S., Westendorf J. J. & Lian J. B. (20110328). The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. : Molecular cancer therapeutics.

Chicago

Pratap Jitesh, Akech Jacqueline, Wixted John J, Szabo Gabriela, Hussain Sadiq, McGee-Lawrence Meghan E, Li Xiaodong, Bedard Krystin, Dhillon Robinder J, van Wijnen Andre J, Stein Janet L, Stein Gary S, Westendorf Jennifer J and Lian Jane B. 20110328. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. : Molecular cancer therapeutics.

Harvard

Pratap J., Akech J., Wixted J. J., Szabo G., Hussain S., McGee-Lawrence M. E., Li X., Bedard K., Dhillon R. J., van Wijnen A. J., Stein J. L., Stein G. S., Westendorf J. J. and Lian J. B. (20110328). The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. : Molecular cancer therapeutics.

MLA

Pratap Jitesh, Akech Jacqueline, Wixted John J, Szabo Gabriela, Hussain Sadiq, McGee-Lawrence Meghan E, Li Xiaodong, Bedard Krystin, Dhillon Robinder J, van Wijnen Andre J, Stein Janet L, Stein Gary S, Westendorf Jennifer J and Lian Jane B. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. : Molecular cancer therapeutics. 20110328.